Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Nikhil Wagle, MD


Medical Oncology

No Ratings Available - Why Not? Make an Appointment

Physician

  • Physician
  • Assistant Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast cancer
  • Cancer genomics
  • Precision/personalized cancer medicine
  • Therapeutic resistance

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Board Certification:

  • Internal Medicine, 2009
  • Medical Oncology, 2012

Fellowship:

  • Dana-Farber/Partners CancerCare

Residency:

  • Brigham and Women's Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Research

Cell line-specific network models of ER+ breast cancer identify potential PI3Ka inhibitor resistance mechanisms and drug combinations. Cancer Res. 2021 Jul 13.
View in: PubMed

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience. J Natl Compr Canc Netw. 2021 Mar 24; 1-8.
View in: PubMed

Expansion sequencing: Spatially precise in situ transcriptomics in intact biological systems. Science. 2021 01 29; 371(6528).
View in: PubMed

Opposing immune and genetic mechanisms shape oncogenic programs in synovial sarcoma. Nat Med. 2021 02; 27(2):289-300.
View in: PubMed

Genomic Characterization of de novo Metastatic Breast Cancer. Clin Cancer Res. 2021 Feb 15; 27(4):1105-1118.
View in: PubMed

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307.
View in: PubMed

Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER+ Metastatic Breast Cancer. Clin Cancer Res. 2020 11 15; 26(22):5974-5989.
View in: PubMed

The Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Hormone Receptor-Positive Metastatic Breast Cancer. Cancer Discov. 2020 08; 10(8):1174-1193.
View in: PubMed

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802.
View in: PubMed

Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4072-4079.
View in: PubMed

Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2556-2564.
View in: PubMed

The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. Nat Med. 2020 02; 26(2):181-187.
View in: PubMed

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. Clin Cancer Res. 2020 06 01; 26(11):2565-2572.
View in: PubMed

FOXA1 upregulation promotes enhancer and transcriptional reprogramming in endocrine-resistant breast cancer. Proc Natl Acad Sci U S A. 2019 Dec 11.
View in: PubMed

Identifying ERBB2 Activating Mutations in HER2-Negative Breast Cancer: Clinical Impact of Institute-Wide Genomic Testing and Enrollment in Matched Therapy Trials. JCO Precis Oncol. 2019; 3.
View in: PubMed

Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments. Nat Cell Biol. 2019 07; 21(7):879-888.
View in: PubMed

MicroRNA-Mediated Suppression of the TGF-ß Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance. Cell Rep. 2019 03 05; 26(10):2667-2680.e7.
View in: PubMed

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2019 Feb 11; 35(2):330-332.
View in: PubMed

Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies. Nat Genet. 2019 02; 51(2):207-216.
View in: PubMed

KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. Cancer Cell. 2018 12 10; 34(6):939-953.e9.
View in: PubMed

Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer. 2018 09; 119(6):707-712.
View in: PubMed

Unraveling the clinicopathological features driving the emergence of ESR1 mutations in metastatic breast cancer. NPJ Breast Cancer. 2018; 4:22.
View in: PubMed

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine. Cancer Discov. 2018 09; 8(9):1096-1111.
View in: PubMed

Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects. Clin Pharmacol Ther. 2018 05; 103(5):778-786.
View in: PubMed

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors. Oncologist. 2018 04; 23(4):401-e38.
View in: PubMed

Allele-Specific Chromatin Recruitment and Therapeutic Vulnerabilities of ESR1 Activating Mutations. Cancer Cell. 2018 02 12; 33(2):173-186.e5.
View in: PubMed

Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2018 02 20; 36(6):543-553.
View in: PubMed

Characterizing reduced coverage regions through comparison of exome and genome sequencing data across 10 centers. Genet Med. 2018 08; 20(8):855-866.
View in: PubMed

Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017 11 06; 8(1):1324.
View in: PubMed

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017 Aug 09; 9(402).
View in: PubMed

Multiplexed Elimination of Wild-Type DNA and High-Resolution Melting Prior to Targeted Resequencing of Liquid Biopsies. Clin Chem. 2017 Oct; 63(10):1605-1613.
View in: PubMed

Systematic genomic and translational efficiency studies of uveal melanoma. PLoS One. 2017; 12(6):e0178189.
View in: PubMed

Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study. Genet Med. 2017 07; 19(7):787-795.
View in: PubMed

The fuzzy world of precision medicine: deliberations of a precision medicine tumor board. Per Med. 2017 Jan; 14(1):37-50.
View in: PubMed

The impact of tumor profiling approaches and genomic data strategies for cancer precision medicine. Genome Med. 2016 07 26; 8(1):79.
View in: PubMed

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 07 07; 99(1):246.
View in: PubMed

Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 06 02; 98(6):1051-1066.
View in: PubMed

Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016 10; 18(10):1011-9.
View in: PubMed

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer. Invest New Drugs. 2015 Oct; 33(5):1108-14.
View in: PubMed

Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma. JAMA Oncol. 2015 May; 1(2):238-44.
View in: PubMed

Precision medicine in breast cancer: genes, genomes, and the future of genomically driven treatments. Curr Oncol Rep. 2015 Apr; 17(4):15.
View in: PubMed

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations. Cancer Discov. 2015 Apr; 5(4):358-67.
View in: PubMed

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses? EBioMedicine. 2015 Jan; 2(1):2-4.
View in: PubMed

Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):E5564-73.
View in: PubMed

ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res. 2014 Dec 01; 74(23):7079-89.
View in: PubMed

Response and acquired resistance to everolimus in anaplastic thyroid cancer. N Engl J Med. 2014 Oct 09; 371(15):1426-33.
View in: PubMed

Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 2014 Oct; 4(10):1140-53.
View in: PubMed

Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nat Biotechnol. 2014 Jul; 32(7):644-52.
View in: PubMed

Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
View in: PubMed

Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine. Nat Med. 2014 Jun; 20(6):682-8.
View in: PubMed

Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 2014 May; 4(5):546-53.
View in: PubMed

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov. 2014 Jan; 4(1):94-109.
View in: PubMed

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discov. 2014 Jan; 4(1):61-8.
View in: PubMed

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma. Invest New Drugs. 2014 Feb; 32(1):178-87.
View in: PubMed

Processes and preliminary outputs for identification of actionable genes as incidental findings in genomic sequence data in the Clinical Sequencing Exploratory Research Consortium. Genet Med. 2013 Nov; 15(11):860-7.
View in: PubMed

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
View in: PubMed

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
View in: PubMed

Clinical analysis and interpretation of cancer genome data. J Clin Oncol. 2013 May 20; 31(15):1825-33.
View in: PubMed

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov. 2013 Mar; 3(3):350-62.
View in: PubMed

Discordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification. . 2012 Oct; 11(10):2301-5.
View in: PubMed

A landscape of driver mutations in melanoma. Cell. 2012 Jul 20; 150(2):251-63.
View in: PubMed

Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012 May 09; 485(7399):502-6.
View in: PubMed

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012 Jan; 2(1):82-93.
View in: PubMed

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011 Aug 01; 29(22):3085-96.
View in: PubMed

Biomarker-based prediction of response to therapy for colorectal cancer: current perspective. Am J Clin Pathol. 2010 Sep; 134(3):478-90.
View in: PubMed

Cardiac presentation of anaplastic large-cell lymphoma. J Clin Oncol. 2010 Jul 01; 28(19):e314-6.
View in: PubMed

A p53-dependent checkpoint pathway prevents rereplication. Mol Cell. 2003 Apr; 11(4):997-1008.
View in: PubMed

Re: Surveys identify barriers to participation in clinical trials. J Natl Cancer Inst. 2001 Feb 07; 93(3):238-9.
View in: PubMed

Rvb1p and Rvb2p are essential components of a chromatin remodeling complex that regulates transcription of over 5% of yeast genes. J Biol Chem. 2001 May 11; 276(19):16279-88.
View in: PubMed

Measuring the incremental cost of clinical cancer research. J Clin Oncol. 2001 Jan 01; 19(1):105-10.
View in: PubMed

Analysis of JNK, Mdm2 and p14(ARF) contribution to the regulation of mutant p53 stability. J Mol Biol. 2000 Jan 28; 295(4):1009-21.
View in: PubMed

B-lymphocyte signaling receptors and the control of class-II antigen processing. Curr Top Microbiol Immunol. 2000; 245(2):101-26.
View in: PubMed

CD19 regulates B cell antigen receptor-mediated MHC class II antigen processing. Vaccine. 1999 Sep; 18(3-4):376-86.
View in: PubMed

Regulation of B cell receptor-mediated MHC class II antigen processing by FcgammaRIIB1. J Immunol. 1999 Mar 01; 162(5):2732-40.
View in: PubMed

Signaling through the B cell antigen receptor regulates discrete steps in the antigen processing pathway. Cell Immunol. 1998 Feb 25; 184(1):1-11.
View in: PubMed

Generation and characterization of monoclonal antibodies to the human thyrotropin (TSH) receptor: antibodies can bind to discrete conformational or linear epitopes and block TSH binding. Endocrinology. 1995 Jul; 136(7):2817-24.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top